KZR - NASDAQ

Kezar Life Sciences, Inc.

KZR·NASDAQ

$7.29

+0.0000%

HealthcareBiotechnology

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$53.86M

EPS-7.6600

P/E Ratio-0.82

Earnings Date08/06/2026

kzr

Net Interest Income

Last Annual Value

4.44M

3-Year CAGR

15%

5-Year CAGR

30%

10-Year CAGR

Adjust for Inflation

Kezar Life Sciences, Inc. Competitors Analysis of Net Interest Income

KZR · NASDAQ

Company	Net Interest Income	CAGR 3Y	CAGR 5Y	CAGR 10Y
Kezar Life Sciences, Inc. NASDAQ:KZR	4.44M	-22.5%	173.6%	N/A
OnKure Therapeutics, Inc. NASDAQ:OKUR	3.44M	28.5%	N/A	N/A
Actinium Pharmaceuticals, Inc. AMEX:ATNM	3.88M	7.7%	82.8%	N/A
Xilio Therapeutics, Inc. NASDAQ:XLO	3.40M	N/A	N/A	N/A
Mersana Therapeutics, Inc. NASDAQ:MRSN	4.56M	-17.1%	N/A	43.8%
PDS Biotechnology Corporation NASDAQ:PDSB	-4.12M	N/A	N/A	N/A
X4 Pharmaceuticals, Inc. NASDAQ:XFOR	-4.30M	N/A	N/A	N/A
Aligos Therapeutics, Inc. NASDAQ:ALGS	2.16M	20.3%	75.0%	N/A

Kezar Life Sciences, Inc. Fair Value Envelope

KZR · NASDAQ

Our analysis suggests that KZR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $7.29, this represents a potential HIDDEN relative to our calculated worth for Kezar Life Sciences, Inc..

HIDDEN

Intrinsic Value

Current Price: $7.29

Related Guides

Blog Categories

Continue your KZR research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.